These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15614340)

  • 21. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin therapy in type 2 diabetes.
    Davis T; Edelman SV
    Med Clin North Am; 2004 Jul; 88(4):865-95, x. PubMed ID: 15308383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
    Tousoulis D; Koniari K; Antoniades C; Miliou A; Noutsou M; Nikolopoulou A; Papageorgiou N; Marinou K; Stefanadi E; Stefanadis C
    Clin Ther; 2010 Sep; 32(10):1720-8. PubMed ID: 21194594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
    Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.
    Sgarra L; Addabbo F; Potenza MA; Montagnani M
    Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1171-82. PubMed ID: 22374753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oral drugs for diabetes--update of current use and availability].
    Niskanen L
    Duodecim; 2004; 120(8):983-90. PubMed ID: 15185512
    [No Abstract]   [Full Text] [Related]  

  • 32. The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
    Brown MN
    Med Health R I; 2000 Apr; 83(4):118-20. PubMed ID: 10821014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.
    Dunn FL; Higgins LS; Fredrickson J; DePaoli AM;
    J Diabetes Complications; 2011; 25(3):151-8. PubMed ID: 20739195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes.
    Desch S; Sonnabend M; Niebauer J; Sixt S; Sareban M; Eitel I; de Waha S; Thiele H; Blüher M; Schuler G
    Diabetes Obes Metab; 2010 Sep; 12(9):825-8. PubMed ID: 20649635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosiglitazone causes endothelial dysfunction in humans.
    Perampaladas K; Gori T; Parker JD
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):260-5. PubMed ID: 22053074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin resistance and the endothelium.
    Hsueh WA; Lyon CJ; Quiñones MJ
    Am J Med; 2004 Jul; 117(2):109-17. PubMed ID: 15234647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.
    Walcher T; Walcher D; Hetzel J; Mielke C; Rau M; Rittig K; Balletshofer B; Schwedhelm E; Hombach V; Böger RH; Koenig W; Marx N
    Diab Vasc Dis Res; 2010 Jul; 7(3):178-85. PubMed ID: 20460360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspective in insulin therapy in the management of diabetes mellitus.
    Garg MK
    J Indian Med Assoc; 2002 Mar; 100(3):194-5, 202. PubMed ID: 12408284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The new rosiglitazone story: its place today in type 2 diabetes management.
    Ambery P; Pandya B
    Prim Care Diabetes; 2009 Feb; 3(1):57-9. PubMed ID: 19269912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
    Pistrosch F; Passauer J; Fischer S; Fuecker K; Hanefeld M; Gross P
    Diabetes Care; 2004 Feb; 27(2):484-90. PubMed ID: 14747233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.